{"id":36453,"date":"2018-05-24T07:56:47","date_gmt":"2018-05-24T05:56:47","guid":{"rendered":"https:\/\/cms.munich-startup.net\/?p=36453"},"modified":"2021-03-31T22:09:31","modified_gmt":"2021-03-31T20:09:31","slug":"biotech-press-lounge-2018","status":"publish","type":"post","link":"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/","title":{"rendered":"Biotech Press Lounge: New ways to invest in cancer drugs"},"content":{"rendered":"<div class=\"entry-content\"><p><strong>The Biotech Press Lounge has established itself as a networking event for the Martinsried Science Campus. Over 100 guests from the biotech, pharmaceutical, and venture capital industries met on May 16, 2018, at the 8th Biotech Press Lounge in the Faculty Club G2B (Gateway to Biotech) to listen to renowned speakers and engage in discussion afterwards.<\/strong><\/p>\n<blockquote><p>\u201cI am very pleased that we have been able to attract such high-caliber speakers for the Biotech Press Lounge, who will not only be coming to the IZB for this event, but will also be accompanying us regularly throughout the year,\u201d<\/p><\/blockquote>\n<p>so <strong>Dr. Peter Hanns Zobel<\/strong>, Managing Director of the IZB.<\/p>\n<p>The event was moderated by <a href=\"\/en\/19098\/asked-at-the-izb\/\" target=\"_blank\" rel=\"noopener\">IZB<\/a> the editor-in-chief of FOCUS Gesundheit, <strong>Jochen Niehaus<\/strong>, win. Ph.D. Timothy Luker, Senior Director, Emerging Technology &amp; Innovation, Business Development at Eli Lilly, explained the pharmaceutical company&#039;s external innovation strategy.<\/p>\n<p>Prof. Dr. Patrick Baeuerle, Managing Director of MPM Capital, presented a new approach to investing in cancer drugs through the company Cullinan Oncology. Stephen S. Yoder, CEO of Pieris Pharmaceuticals Inc., spoke about the challenges and opportunities of building a sustainable, innovative biotech company in Germany and beyond.<\/p>\n<blockquote><p>\u201cThe outstanding technological developments and the good financing of Pieris, one of our most successful companies at the IZB, show how exceptionally innovative the life science location in Munich is,\u201d<\/p><\/blockquote>\n<p>Zobel commented on the presentations.<\/p>\n<h3>High-quality medicines that improve lives<\/h3>\n<p>The first speaker was Ph.D. <strong>Timothy Luker<\/strong>, Senior Director, Emerging Technology &amp; Innovation, Business Development at Eli Lilly, on the development of high-quality medicines and the necessary search for external innovations.<\/p>\n<blockquote><p>\u201cSince Eli Lilly and Co. was founded in 1876, our mission has remained unchanged: to develop high-quality medicines that improve lives,\u201d<\/p><\/blockquote>\n<p>says Luker.<\/p>\n<blockquote><p>&quot;We know we can&#039;t do it alone and must be innovative in our scientific and collaborative relationships to develop medicines. We are excited about groundbreaking innovations in oncology, immunology, neurogeneration, pain therapy, and diabetes. This gives us exciting models to bring the best science into our pipeline,&quot;<\/p><\/blockquote>\n<p>Luker explains further.<\/p>\n<p>The second speaker, <strong>Prof. Dr. Patrick Baeuerle<\/strong>, Managing Director of MPM Capital, presented a new way to invest in cancer drugs and explained the concept of Cullinan Oncology. Founded in 2017 with Owen Hughes and Ansbert Gadicke, the company is based in Cambridge, Massachusetts, USA, and currently has 10 employees. Investors include the UBS Oncology Impact Fund, managed by MPM Capital, and F2 Ventures.<\/p>\n<blockquote><p>\u201cCullinan Oncology received a Series A investment of $150 million, which will fund five to eight new companies developing new cancer drugs under its umbrella,\u201d<\/p><\/blockquote>\n<p>Baeuerle is happy.<\/p>\n<h3>\u201cThe second half of the year will be exciting for Pieris\u201d<\/h3>\n<p><strong>Stephen Yoder<\/strong>, CEO of Pieris Pharmaceuticals, based at the IZB in Weihenstephan and Boston, discussed Pieris&#039; Anticalin\u00ae drug discovery and development platform as well as the challenges and opportunities of building a sustainable innovative biotech company in Germany and beyond.<\/p>\n<blockquote><p>\u201cPieris uses its unique technology to develop treatments for oncological and respiratory diseases,\u201d<\/p><\/blockquote>\n<p>explained Yoder.<\/p>\n<p>The company recently announced a collaboration with Seattle Genetics in the field of immuno-oncology, which represents an important addition to its portfolio of strategic partnerships, which also includes AstraZeneca and Servier.<\/p>\n<blockquote><p>\u201cThe second half of the year will be exciting for Pieris as we intend to publish data for three of our clinical programs,\u201d<\/p><\/blockquote>\n<p>said Yoder at the end of his lecture.<\/p>\n<p>The next Biotech Press Lounge will take place on October 11, 2018. As the event is limited to 100 guests, a <a href=\"https:\/\/www.izb-online.de\/\" target=\"_blank\" rel=\"noopener\">Registration required<\/a>.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>The Biotech Press Lounge has established itself as a networking event for the Martinsried Science Campus. Over 100 guests from the biotech, pharmaceutical, and venture capital industries met on May 16, 2018, at the 8th Biotech Press Lounge in the Faculty Club G2B (Gateway to Biotech) to listen to renowned speakers and exchange ideas. &quot;It...<\/p>","protected":false},"author":3,"featured_media":36461,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1,5635],"tags":[1499],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biotech Presse-Lounge: Neue Wege in Krebsmedikamente zu investieren - Munich Startup<\/title>\n<meta name=\"description\" content=\"\u00dcber 100 G\u00e4ste aus der Biotech-, Pharma- und Venture Capital-Branche trafen sich am 16. Mai 2018 auf der 8. Biotech Presse-Lounge im Faculty Club G2B.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biotech Presse-Lounge: Neue Wege in Krebsmedikamente zu investieren - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"\u00dcber 100 G\u00e4ste aus der Biotech-, Pharma- und Venture Capital-Branche trafen sich am 16. Mai 2018 auf der 8. Biotech Presse-Lounge im Faculty Club G2B.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:author\" content=\"https:\/\/www.facebook.com\/profile.php?id=100009572160192\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-24T05:56:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-31T20:09:31+00:00\" \/>\n<meta name=\"author\" content=\"Florian Deglmann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@FlorianDeglmann\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Florian Deglmann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/\",\"url\":\"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/\",\"name\":\"Biotech Presse-Lounge: Neue Wege in Krebsmedikamente zu investieren - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2018\/05\/IZB-Presselounge-2018.jpg\",\"datePublished\":\"2018-05-24T05:56:47+00:00\",\"dateModified\":\"2021-03-31T20:09:31+00:00\",\"author\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/2371b77bb47cd783e9e1f88e88d9f251\"},\"description\":\"\u00dcber 100 G\u00e4ste aus der Biotech-, Pharma- und Venture Capital-Branche trafen sich am 16. Mai 2018 auf der 8. Biotech Presse-Lounge im Faculty Club G2B.\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2018\/05\/IZB-Presselounge-2018.jpg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2018\/05\/IZB-Presselounge-2018.jpg\",\"width\":2184,\"height\":1454,\"caption\":\"Biotech Presse-Lounge 2018\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biotech Presse-Lounge: Neue Wege in Krebsmedikamente zu investieren\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/2371b77bb47cd783e9e1f88e88d9f251\",\"name\":\"Florian Deglmann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1e3087740aeaedbec23f0c7300f1beeb?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1e3087740aeaedbec23f0c7300f1beeb?s=96&d=blank&r=g\",\"caption\":\"Florian Deglmann\"},\"description\":\"Der Exil-N\u00fcrnberger erforschte bis April 2019 als Redakteur die M\u00fcnchner Startup-Szene.\",\"sameAs\":[\"http:\/\/cms.munich-startup.net\",\"https:\/\/www.facebook.com\/profile.php?id=100009572160192\",\"https:\/\/x.com\/FlorianDeglmann\"],\"url\":\"https:\/\/cms.munich-startup.net\/en\/author\/deglmann\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2018\/05\/IZB-Presselounge-2018.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2184\" \/>\n\t<meta property=\"og:image:height\" content=\"1454\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biotech Press Lounge: New ways to invest in cancer drugs - Munich Startup","description":"Over 100 guests from the biotech, pharmaceutical and venture capital industries met on May 16, 2018 at the 8th Biotech Press Lounge in the Faculty Club G2B.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/","og_locale":"en_US","og_type":"article","og_title":"Biotech Presse-Lounge: Neue Wege in Krebsmedikamente zu investieren - Munich Startup","og_description":"\u00dcber 100 G\u00e4ste aus der Biotech-, Pharma- und Venture Capital-Branche trafen sich am 16. Mai 2018 auf der 8. Biotech Presse-Lounge im Faculty Club G2B.","og_url":"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_author":"https:\/\/www.facebook.com\/profile.php?id=100009572160192","article_published_time":"2018-05-24T05:56:47+00:00","article_modified_time":"2021-03-31T20:09:31+00:00","author":"Florian Deglmann","twitter_card":"summary_large_image","twitter_creator":"@FlorianDeglmann","twitter_site":"@munich_startup","twitter_misc":{"Written by":"Florian Deglmann","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/","url":"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/","name":"Biotech Press Lounge: New ways to invest in cancer drugs - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2018\/05\/IZB-Presselounge-2018.jpg","datePublished":"2018-05-24T05:56:47+00:00","dateModified":"2021-03-31T20:09:31+00:00","author":{"@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/2371b77bb47cd783e9e1f88e88d9f251"},"description":"Over 100 guests from the biotech, pharmaceutical and venture capital industries met on May 16, 2018 at the 8th Biotech Press Lounge in the Faculty Club G2B.","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2018\/05\/IZB-Presselounge-2018.jpg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2018\/05\/IZB-Presselounge-2018.jpg","width":2184,"height":1454,"caption":"Biotech Presse-Lounge 2018"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/en\/36453\/biotech-press-lounge-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"Biotech Presse-Lounge: Neue Wege in Krebsmedikamente zu investieren"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/2371b77bb47cd783e9e1f88e88d9f251","name":"Florian Deglmann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1e3087740aeaedbec23f0c7300f1beeb?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1e3087740aeaedbec23f0c7300f1beeb?s=96&d=blank&r=g","caption":"Florian Deglmann"},"description":"The exiled Nuremberg resident researched the Munich startup scene as an editor until April 2019.","sameAs":["http:\/\/cms.munich-startup.net","https:\/\/www.facebook.com\/profile.php?id=100009572160192","https:\/\/x.com\/FlorianDeglmann"],"url":"https:\/\/cms.munich-startup.net\/en\/author\/deglmann\/"}]},"og_image":[{"width":2184,"height":1454,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2018\/05\/IZB-Presselounge-2018.jpg","type":"image\/jpeg"}]},"_showyear":"","_inactive":"","_show_financing":"","_hide_on_map":"","_edit_lock":"1527150192:24","_edit_last":"24","_yoast_wpseo_focuskw":"Biotech Presse-Lounge","_yoast_wpseo_metadesc":"\u00dcber 100 G\u00e4ste aus der Biotech-, Pharma- und Venture Capital-Branche trafen sich am 16. Mai 2018 auf der 8. Biotech Presse-Lounge im Faculty Club G2B.","_yoast_wpseo_linkdex":"93","_thumbnail_id":"36461","wbounce_status":"default","_yoast_wpseo_primary_category":"","_yoast_wpseo_focuskw_text_input":"Biotech Presse-Lounge","_yoast_wpseo_content_score":"30","ms_image_format":"","_ms_image_format":"","ms_dachzeile":"","_ms_dachzeile":"","ms_bump_post_date":"","_ms_bump_post_date":"","guest_author_name":"","_guest_author_name":"","guest_author_image":"","_guest_author_image":"","guest_author_description":"","_guest_author_description":"","ms_post_image_caption":"","_ms_post_image_caption":"","ms_post_image_credit":"","_ms_post_image_credit":"","suppress_startupbox":"","_suppress_startupbox":"","_yoast_wpseo_estimated-reading-time-minutes":"","_wp_old_date":"","_yoast_wpseo_title":"","_yoast_wpseo_wordproof_timestamp":"","footnotes":"","easy_language_simplification_original_id":"","easy_language_source_language":"","easy_language_simplification_language":"","easy_language_api":"","easy_language_prevent_automatic_mode":"","_wp_old_slug":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","easy_language_simplification_state_changed_from":"","easy_language_de_EL_changed":"","ms_competition_deadline":"","_ms_competition_deadline":"","_wpbitly":"","enclosure":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","wbounce_template":"","wbounce_title":"","wbounce_text":"","wbounce_cta":"","wbounce_url":"","wbounce_override":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_oembed_7131efca3705e16bd9da2c41df237660":"","_oembed_time_7131efca3705e16bd9da2c41df237660":"","_pprredirect_type":"","_pprredirect_url":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":"","_newsletterglue":"","easy_language_text_language":"","_wp_desired_post_slug":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/36453"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=36453"}],"version-history":[{"count":1,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/36453\/revisions"}],"predecessor-version":[{"id":70995,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/36453\/revisions\/70995"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/36461"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=36453"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/categories?post=36453"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=36453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}